Human EML4-ALK Fusion Gene Detection Kit

Product Features:

• High Sensitivity:  accurately detect 1% of mutant DNA from 10ng of the wild-type gene
• High Specificity:  effectively improve the testing specificity by ARMS-PCR detection technology
• High Accuracy: closed tube reaction effectively prevent false negative and false positive results through the standard internal system and UNG enzyme system
• Quick & Easy: easy to operate with reliable results analysis, 90 mins to complete

Product Information

Clinical Significance

ALK(anaplastic lymphoma kinase)gene and EML4(echinodermmicro tubule associated proteinlike 4)fusion gene is one of the newly discovered molecular targets of NSCLC. With biological activation, the activated EML4-ALK fusion gene affects cell proliferation,differentiation and apoptosis by activating and transmitting downstream substrate molecules.

The Positive rate of ALK fusion of adenocarcinoma is 5.1%, but the positive rate of ALK fusion gene in adenocarcinoma with wild-type EGFR and KRAS was as high as 30 to 42%. Some studies have shown that age is a significant independent predictor of ALK-positive NSCLC, study has found that the incidence of ALK fusion positivity was as high as 18.5% in patients younger than 51 years old, and the incidence of ALK fusions was also found to be nearly 20% in patients younger than 40 years of age.

For patients with a positive EML4-ALK fusion gene, good clinical results can be obtained with small molecule inhibitors targeting theALK genes, such as crizotinib, ceritinib and aletinib.

EML4-ALK Gene Corresponding Targeted Drugs